Axcan Photofrin "approvable" for Barrett’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Axcan expects approval of Photofrin (porfimer sodium) for treatment of high grade dysplasia associated with Barrett's esophagus "in the next few months." FDA issued an "approvable" letter for the new indication Nov. 29. The firm has already submitted the major portion of data requested in the letter - two-year follow-up results - and expects to respond to FDA's other requests by the end of 200
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.